Biotech SPACs Can Expect a Good Runway as Investors Focus on Quality: Report

Biotech

The flight to quality is real, BioSpace reports.

Carve-outs could be the next big SPAC target according to the report, although many investors don’t realize that many aren’t public-ready. They don’t have the appropriate audited financials. And developing them takes more time than people expect.

To put this in perspective, it may take 6 to 8 months to find the right company, and 12 to 18 months to get the financials in order and audited. If the SPAC was formed for a two-year duration, there’s not enough time to get a carve-out ready unless it’s already prepared. Read more.

Total
0
Shares
Related Posts